however, it was associated with the highest rate of gastrointestinal adverse events ( A systematic review and meta-analysis conducted to investigate the efficacy of tirzepatide on glycated hemoglobin, fasting serum glucose, and body weight in patients with uncontrolled T2DM reported that tirzepatide significantly improved glycemic control and body weight with an acceptable safety profile ( The FDA has approved liraglutide (a maintenance dose of 3 mg injected daily), subcutaneous semaglutide (2.4 mg injected once weekly), and tirzepatide (515 mg injected once weekly) for chronic weight management in adults with body mass index (BMI) of 30 kg/m 2 or greater, or with a BMI of 27 kg/m 2 or greater with at least one weight-related condition (such as high BP, T2DM, or high cholesterol) to be used in addition to a reduced calorie diet and increased physical activity ( Overall, robust findings have showed that GLP-1 RAs effectively promote weight loss

Prescribing one without checking the others is how women end up on a treatment that helps less than it should while the real driver goes unexamined
Make sure your healthcare provider explains these values and their implications for your liver health
J Pharm Bioallied Sci 16:S243S246
It has undergone a lot of clinical testing (the STEP trial program included more than 4,500 people) that shows it works and is safe, which supports regulatory submissions in big countries